Abstract
Regulatory authorities, including the US Food and Drug Administration (FDA), have accelerated diagnostic and therapeutic approvals during the coronavirus disease 2019 (COVID-19) pandemic. Accelerated clinical development and approvals have resulted in vaccine programs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, some individuals remain at high risk for the progression of COVID-19. In the US, the FDA has given Emergency Use Authorization (EUA) for two neutralizing therapeutic monoclonal antibody ‘cocktails,’ casirivimab and imdevimab (REGEN-COV), bamlanivimab and etesevimab, and one monotherapy, bamlanivimab, for prophylactic post-exposure therapy in individuals at high risk of progressing to severe COVID-19. Preclinical and clinical studies showed consistent effectiveness of REGEN-COV against current variants of SARS-CoV-2. On 21st November 2020, the FDA approved an initial EUA for REGEN-COV to treat mild to moderate COVID-19 in adults and in children 12 years or older with exposure to SARS-CoV-2 at high risk for progression to severe COVID-19. On 30th July 2021, the FDA updated its EUA for REGEN-COV for emergency use as post-exposure prophylactic to prevent COVID-19 progression in adults and children aged 12 years or older. This Editorial aims to provide an update on accelerated regulatory authorization for post-exposure prophylactic neutralizing monoclonal antibodies to SARS-CoV-2 for individuals at high risk for COVID-19.
【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Vaccine, coronavirus, pandemic, therapy, severe COVID-19, children, monoclonal antibody, diagnostic, drug, progression, Prophylactic, severe acute respiratory syndrome Coronavirus, FDA, Emergency use authorization, bamlanivimab, EUA, Moderate COVID-19, Regulatory, REGEN-COV, Casirivimab, Imdevimab, etesevimab, therapeutic, Effectiveness, Clinical studies, Mild, Neutralizing, respiratory, monotherapy, neutralizing monoclonal antibodies, neutralizing monoclonal antibody, Emergency use, food, clinical study, Emergency, high risk, exposure to, mild to moderate, US Food and Drug Administration, COVID-19 progression, acute respiratory syndrome, Older, Regulatory Authorities, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, individual, approval, clinical development, treat, approvals, authorization, variants of SARS-CoV-2, editorial, Prevent, initial, approved, accelerated, Preclinical, 【제목키워드】 COVID-19, SARS-CoV-2, individual,